Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed) | PAR 22 038

Frequently Asked Questions (FAQs): NIH PAR 22 038 (R21) Neuromodulation and Neurostimulation Devices for Mental Health

1) What is this funding opportunity (PAR 22 038) trying to support?

This NIH opportunity supports early-stage research and development projects focused on creating the next generation of neuromodulation and neurostimulation devices for mental health disorders. The emphasis is on ambitious device development work that can de-risk a new technical direction and produce a compelling prototype or proof of concept.

2) What grant mechanism is used, and what does that imply?

The opportunity uses the NIH R21 mechanism. R21 awards are typically intended for exploratory, potentially high-impact development efforts that demonstrate feasibility, reduce technical risk, and generate proof-of-concept results rather than late-stage validation or full-scale clinical efficacy testing.

3) Are clinical trials allowed under this FOA?

No. Clinical trials are not allowed under this FOA. The work should focus on device development, engineering validation, and other preclinical or non-trial human work that does not meet the NIH definition of a clinical trial.

4) If clinical trials are not allowed, what kinds of activities are emphasized?

The FOA emphasizes device development and engineering validation, along with preclinical testing and other non-trial human work (as long as it does not meet the definition of a clinical trial). The goal is to advance technology readiness through prototyping, proof-of-concept demonstrations, and validation of performance-relevant features.

5) What are the two main project types NIH is looking for?

The FOA highlights two categories: (1) entirely novel brain stimulation devices that go beyond common electrical or magnetic stimulation approaches, and (2) major enhancements to devices that are already FDA-approved or FDA-cleared, but only when the improvements are substantial and enable clearly new capabilities.

6) What counts as an "entirely novel" brain stimulation device in this announcement?

Novel approaches are expected to go beyond typical electrical or magnetic stimulation modalities that dominate current clinical and commercial tools. NIH signals interest in new stimulation techniques that could deliver better spatiotemporal precision, enable multi-focal stimulation, and support closed-loop operation (integrated sensing plus stimulation that adapts to measured signals).

7) What does "spatiotemporal precision" mean in the context of this FOA?

Spatiotemporal precision refers to improved ability to target smaller neural populations more accurately (spatial precision) and to control the timing and pattern of stimulation more precisely (temporal precision). NIH indicates interest in technologies that improve both where stimulation is delivered and how precisely it is delivered over time.

8) What is "multi-focal stimulation" and why is it mentioned?

Multi-focal stimulation refers to coordinated targeting of more than one brain region or network node. It is mentioned as a desirable direction because mental health disorders may involve distributed brain networks, and coordinated stimulation across multiple sites may enable more effective or flexible therapeutic strategies.

9) What is a "closed-loop" neuromodulation approach as described here?

A closed-loop approach integrates sensing and stimulation so the device can adjust stimulation parameters in response to measured neural or physiological signals. The FOA highlights interest in systems that can adapt in real time (or near real time) based on relevant measured biomarkers or signals.

10) Can applicants propose improvements to existing FDA-approved or FDA-cleared devices?

Yes, but only if the enhancements are major and enable clearly new capabilities. The FOA explicitly discourages incremental modifications and routine refinements, including minor software updates, as being out of scope.

11) What kinds of improvements to existing devices does NIH consider meaningful?

The announcement calls out substantial improvements that materially advance capabilities such as spatial resolution, depth of delivery, and overall precision. Proposed enhancements should represent leaps in performance or functionality, not small product tweaks.

12) Are incremental software updates or routine product refinements responsive to this FOA?

No. The FOA indicates that incremental modifications are not the goal and gives examples such as minor software updates or routine refinements as being out of scope.

13) What outcomes should a competitive R21 project aim to produce?

Based on the stated purpose of the R21 mechanism and the FOA emphasis, projects should aim to de-risk a new technical direction and produce a compelling prototype or proof of concept, supported by engineering validation and other relevant non-clinical-trial evidence.

14) Why does NIH emphasize multidisciplinary teams for this opportunity?

NIH expects multidisciplinary applications because successful neuromodulation device development requires alignment between biological rationale, engineering feasibility, clinical practicality, and regulatory realities. The FOA signals that this mix reduces the chance that a technically impressive prototype fails later due to weak mechanistic justification, poor fit with clinical constraints, or an unrealistic regulatory pathway.

15) What disciplines or expertise areas does NIH expect to see represented?

The FOA points to a mix that includes systems neuroscience (targets, biomarkers, mechanistic rationale), engineering (device creation and validation, control systems), clinical expertise (real-world clinical constraints and patient needs, even without trials), and regulatory affairs (designing development work with an eventual FDA pathway in mind).

16) Is regulatory strategy relevant even though this is early-stage device development?

Yes. The FOA explicitly notes regulatory affairs as part of the expected team composition, with the intent that development work be designed with an eventual FDA pathway in mind.

17) Who is eligible to apply?

Eligibility is broad. Eligible applicants include many government entities (state, county, city/township, special districts), public and private institutions of higher education, independent school districts, federally recognized tribal governments and other tribal organizations, public housing authorities, nonprofits (501(c)(3) and non-501(c)(3)), and for-profit organizations (including small businesses and other for-profits), as well as other eligible entities.

18) Are for-profit organizations allowed to apply?

Yes. The FOA includes for-profit organizations, including small businesses and other for-profits, among eligible applicants.

19) Are nonprofits eligible, and does it matter whether they are 501(c)(3)?

Yes. The FOA includes both 501(c)(3) nonprofits and non-501(c)(3) nonprofits as eligible applicant types.

20) Are Tribal entities and Tribal-serving institutions eligible?

Yes. The eligibility description explicitly includes federally recognized tribal governments and other tribal organizations, Tribally Controlled Colleges and Universities, and other related categories.

21) Are minority-serving institutions or specific institutional categories called out as eligible?

Yes. The FOA explicitly notes categories such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISISs as eligible applicant types.

22) Are faith-based or community-based organizations eligible?

Yes. The FOA explicitly lists faith-based or community-based organizations among eligible applicant types.

23) Can non-U.S. (foreign) organizations apply?

Yes. The FOA explicitly notes non-U.S. (foreign) organizations and regional organizations as eligible applicant types.

24) What agency administers this program and what is the funding category?

This is administered by the National Institutes of Health (NIH). It is described as a discretionary grant in the Health category and references CFDA 93.242.

25) Is this opportunity new or a continuation of a prior program?

It is described as a reissue of an earlier announcement (PAR-18-941), indicating continuity of priorities rather than a completely new program area.

26) What is the award ceiling mentioned in the provided information?

The listed award ceiling is $200,000.

27) What is the posted closing date and the original creation date listed?

The posted original closing date is 2025-01-07, and the FOA is described as originally created on 2021-10-12.

28) What is the overall goal of the FOA in plain terms?

The overall goal is to support ambitious, early-stage device development that can meaningfully advance neuromodulation for mental health by enabling more precise, deeper, more adaptive, and more network-aware stimulation technologies, while avoiding small incremental product changes and excluding clinical trial execution under this specific mechanism.